Answers are grounded in this paper and cite their sources.
Novel phenalkylamines and tryptamines such as psilocybin demonstrate promising nontraditional pharmacological profiles for treating psychiatric syndromes. Structural modifications yield functional selectivity at 5-HT receptors, mitigating hallucinogenic risk while preserving therapeutic efficacy. This study integrates receptor and behavioral data to support phenalkylamines and psilocybin as rational therapeutics for demoralization syndrome and depression-related conditions.
No takes yet. Share an insight, caveat, or question.
Robert B. Kargbo (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: